The DESTINY B04 trial alongside new and improved anti-HER2 armamentarium showed that even nonamplified breast tumors with low HER2 protein expression can benefit from novel anti-HER2 antibody-drug conjugates [6–8]. The gene discussed is ERBB2; the disease is breast neoplasm.